Search

Your search keyword '"Siveke, Jens"' showing total 1,113 results

Search Constraints

Start Over You searched for: Author "Siveke, Jens" Remove constraint Author: "Siveke, Jens"
1,113 results on '"Siveke, Jens"'

Search Results

2. Stroke and myocardial infarction induce neutrophil extracellular trap release disrupting lymphoid organ structure and immunoglobulin secretion

3. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

5. CellViT: Vision Transformers for Precise Cell Segmentation and Classification

6. Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment

7. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation

13. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

16. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization

17. Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?

18. MCL1 as putative target in pancreatoblastoma

19. Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer

20. Prognostic Implications of68Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors

21. 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy

25. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma

26. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression

27. Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.

28. 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy.

29. Prognostic Implications of 68Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.

31. [68Ga]Ga-FAPI versus 2-[18F]FDG PET/CT in patients with autoimmune thyroiditis: a case control study.

32. Theranostics with somatostatin receptor antagonists in SCLC: Correlation of 68Ga-SSO120 PET with immunohistochemistry and survival.

33. Diagnostic Accuracy of68Ga-FAPI Versus18F-FDG PET in Patients with Various Malignancies

34. Multimodal single-cell profiling reveals cancer crosstalk between macrophages and stromal cells in poor prognostic cholangiocarcinoma patients

35. Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance

36. Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization

37. Minimally invasive determination of PDAC subtype and therapy-induced subtype switch by means of circulating cell-free RNA

38. Fibroblast Activation Protein α–Directed Imaging and Therapy of Solitary Fibrous Tumor

40. Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion

42. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

46. 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the68Ga-FAPI PET Observational Trial

47. Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

48. 1294 External validation of machine learning models to predict efficacy and toxicity of immune checkpoint inhibitors using real-world pan cancer cohorts

49. Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription

50. Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence

Catalog

Books, media, physical & digital resources